NOT ALL MINIMAL RESIDUAL DISEASE (MRD) TESTS ARE THE SAME

Circulating tumor DNA (ctDNA) is present at extremely low levels in the blood. RaDaR® offers 10-fold higher sensitivity than other leading MRD tests, allowing more accurate detection of residual or recurring ctDNA

why radar hero graphic

 

Why is this important?

Emerging data from a range of tumor studies demonstrate a correlation between tumor volume and estimated ctDNA fraction and in many cases, ctDNA may be present at close to, or less than, 1 tumor genomic equivalent per 10 mL blood tube for small or low DNA-shedding tumors.

In addition, against a high background of total cell-free DNA (cfDNA), the ctDNA released in the bloodstream prior to treatment is often ≤0.01% among early-stage cancer patients. Therefore, highly sensitive assays such as RaDaR, with a LoD95 of 0.001% variant allele fraction (VAF), are required for the detection of very low, but clinically relevant, ctDNA levels after treatment.
 

1

Detect more patients with residual disease

High sensitivity enables detection of more patients with residual disease and better stratification of those at high risk of relapse.

High sensitivity MRD tests are required to detect microscopic levels of ctDNA. RaDaR detects ctDNA down to 0.001% VAF – 10 times lower than other leading MRD tests.

  RaDaR’S HIGH SENSITIVITY OF 0.001% VAF DETECTS ctDNA IN SAMPLES THAT LESS-SENSITIVE TECHNOLOGIES MAY MISS1-3
 
breast icon

 

Breast cancer

lung cancer icon

 

Non-small cell lung cancer

head neck cancer icon

 

Head & neck cancers

ctDNA detection <0.01% VAF1-3 25% of study samples with detectable ctDNA 36% of study samples with detectable ctDNA 31% of study samples with detectable ctDNA

2

Detect cancer recurrence sooner

High sensitivity enables longer lead times ahead of standard-of-care monitoring tools, such as radiographic imaging. RaDaR’s high sensitivity allows for earlier identification of residual disease and opens up the possibility of intervention prior to overt metastatic disease.

 

MEDIAN LEAD TIMES FOR RELAPSE OR RECURRENCE2-5

graph 3

3

High confidence in results

image circle 4

High specificity means confidence that a positive result is truly positive.

  • Often tests sacrifice specificity to achieve high sensitivity; RaDaR has been designed to balance these two features
  • RaDaR’s unique approach to MRD testing allows for exceptional specificity. The RaDaR workflow:
    • Filters out clonal hematopoiesis of indeterminate potential (CHIP) and germline mutations in the custom assay
    • Uses an aggregated, algorithmic approach for MRD result determination to reduce false positive results with every test
    • Includes a built-in quality control (QC) process to reduce errors

LEARN MORE

cTRAK: Triple-Negative Breast Cancer

RESULTS FROM cTRAK: COMPARISON OF RaDaR TO dPCR (LESS-SENSITIVE TECHNOLOGY)7

When compared to digital PCR (dPCR), a less-sensitive technology, for detecting MRD:

  • RaDaR detected disease recurrence before the dPCR test in nearly half of patients 
  • Results show that RaDaR gives a longer median lead time before radiographic evidence of recurrence: 6.1 months (95% CI: 4.2-10.0) vs. 3.3 months (95% CI: 2.8-6.1)

VIEW POSTER VIEW TABLE

graph 2b

CI = confidence interval; HR = hazard ratio.
* Excluding patient with brain metastases.

References: 1. Lynce P, et al. https://www.inivata.com/wp-content/uploads/2021/12/SABCS-OXEL-11.19.2021-Final.pdf. Accessed February 22, 2023. 2. Gale D, et al. Ann Oncol. 2022;33(5):500-510. 3. Flach S, et al. https://www.inivata.com/wp-content/uploads/2022/09/LIONESS_ESMO2022_FINAL.pdf. Accessed February 24, 2023. 4. Lipsyc-Sharf M, et al. J Clin Oncol. 2022;40:2408-2419. 5. Cutts R, et al. AACR 2021 Abstract 536. 6. Elliot MJ, et al. San Antonio Breast Cancer Symposium, 2022. Abstract P6-01-16. 7. Coakley M, et al. https://www.inivata.com/wp-content/uploads/2023/01/1309878-PD5-03-Coakley-et-al.-Comparison_MRD_assay-1.pdf. Accessed February 22, 2023.

RaDaR MRD testing is validated for the use in multiple solid tumor cancers

BREAST CANCER

COLORECTAL CANCER

LUNG CANCER

HEAD & NECK CANCER

Get started with RaDaR

Contact us to order a RaDaR test.

All fields are mandatory

Zip Code